Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | The impact of omidubicel on access to allogeneic transplantation

Usama Gergis • 24 Apr 2022
The 2022 Tandem Meetings
General Omidubicel

Usama Gergis, MD, MBA, Thomas Jefferson University, Philadelphia, PA, comments on the findings of a hypothetical model investigating the impact of omidubicel on access to allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with high-risk hematological malignancies who lack match related donors. The model showed that omidubicel led to a significant increase in access to allogeneic transplantation, especially in ethnic minorities. In addition, an ongoing Phase III trial demonstrated that omidubicel use led to faster engraftment and a reduction in fungal and viral infections. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Usama Gergis

1:42
Omidubicel vs standard umbilical cord transplantation
Usama Gergis • 24 Apr 2022
1:08
Racial and ethnic disparities in alloHSCT
Usama Gergis • 24 Apr 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals